Regeneron Pharmaceuticals REGN Return on assets
Return on assets at other companies
Other financials
Where this comes from
Calculated from Regeneron Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regeneron Pharmaceuticals's return on assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regeneron Pharmaceuticals's return on assets?
- Regeneron Pharmaceuticals (REGN) reported return on assets of 11.3% in Q1 2026.
- How has Regeneron Pharmaceuticals's return on assets changed year-over-year?
- Regeneron Pharmaceuticals's return on assets decreased by 9.8% year-over-year, from 12.5% to 11.3%.
- What is the long-term trend for Regeneron Pharmaceuticals's return on assets?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's return on assets has grown at a -22.4% compound annual growth rate (CAGR), from 131.5% to 47.8%.
- What does return on assets mean?
- How much profit the company squeezes out of everything it owns.
- How do you interpret return on assets?
- Higher means more productive assets. Unlike ROE, it is unaffected by leverage, so a wide ROE-minus-ROA gap flags a heavily levered balance sheet.
- How does return on assets compare across companies?
- Best compared within an industry — asset intensity varies enormously across sectors. Not meaningful for banks, whose assets are largely financial.